Press Releases

Historic SomaLogic Press Releases >

Date	Title and Summary	Additional Formats
Nov 05, 2020	Fluidigm Announces Third Quarter 2020 Financial Results Third Q uarter T otal R evenue I n creased 50 P ercent to $ 39 .9 M illion Third Q uarter P roduct and Service R evenue I ncreased 34 P ercent to $35 . 3 M illion D riven by COVID-19 T esting GAAP N et L oss in the T hird Q uarter Was $6.0 M illion ; Non-GAAP N et I ncome W as $2.5
Nov 05, 2020	Fluidigm and Healthvana Partner to Offer COVID-19 Test Results Delivery through Innovative Digital Platform Patients Receive Results, Education and Next Steps on Their Mobile Phones to Prevent Further Spread of the Disease SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Nov 03, 2020	Fluidigm Mass Cytometry Technologies, Including CyTOF, Imaging Mass Cytometry and Maxpar Direct, Utilized in More than 100 National Clinical Trials 25 Trials Utilizing Mass Cytometry Initiated in 2020 SOUTH SAN FRANCISCO, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that its mass
Nov 02, 2020	Dante Labs Launching COVID-19 Testing in Europe Utilizing Fluidigm Pathogen Detection Kit on Biomark HD Platform Global Pioneer in Direct-to-Consumer Genomic Testing Chooses Fluidigm Saliva-Based Solution Fluidigm Powered Testing Service to be Rolled Out in Seven European Countries SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative
Oct 08, 2020	Fluidigm to Offer Millions of Advanta COVID-19 Tests at Low Cost to U.S. Colleges and Universities Fluidigm COVID-19 Campus Safeguard Program Improves Availability of Non i nvasive, Saliva-Based SARS-CoV-2 Test s for Higher Education Institutions High-Throughput , Integrated Testing Platform and Reliable Supply Chain SOUTH SAN FRANCISCO, Calif. , Oct.
Oct 06, 2020	Fluidigm Announces Conference Call and Webcast of Third Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2020 financial results on Thursday,
Sep 16, 2020	Fluidigm Joins Global Consortium of Cancer Prevention Experts CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies Principal Focus on Advancing Understanding of Breast and Skin Cancer Risks SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation
Sep 16, 2020	ImmunoGenomics and Vero Diagnostics Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform Regional CLIA-Certified Labs among Growing Number of Customers Expanding SARS-CoV-2 Testing with Fluidigm Technology SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Sep 15, 2020	Fluidigm Announces Agenda for 9th Annual Mass Cytometry Summit Virtual Event Showcases CyTOF Technology and Its Use in High-Parameter Suspension Mass Cytometry and Imaging Mass Cytometry Leading Academic and Pharma Researchers Detail Latest CyTOF Based Discoveries in Infectious Disease, Immunology and the Tumor Microenvironment SOUTH SAN FRANCISCO, Calif.
Sep 08, 2020	Fluidigm Achieves Initial Milestone under NIH Rapid Acceleration of Diagnostics Agreement SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced progress on the Company’s Rapid Acceleration of Diagnostics (RADx)